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Abstract
Introduction Quantitative benefit-risk models (qBRm) applied to vaccines are increasingly used by public health authori-
ties and pharmaceutical companies as an important tool to help decision makers with supporting benefit-risk assessment 
(BRA). However, many publications on vaccine qBRm provide insufficient details on the methodological approaches used. 
Incomplete and/or inadequate qBRm reporting may affect result interpretation and confidence in BRA, highlighting a need 
for the development of standard reporting guidance.
Objectives Our objective was to provide an operational checklist for improved reporting of vaccine qBRm.
Methods The consolidated standards of reporting quantitative Benefit-RIsk models applied to VACcines (BRIVAC) were 
designed as a checklist of key information to report in qBRm scientific publications regarding the assessed vaccines, the 
methodological considerations and the results and their interpretation.
Results In total, 22 items and accompanying definitions, recommendations, explanations and examples were provided and 
divided into six main sections corresponding to the classic subdivisions of a scientific publication: title and abstract (items 
1–2), introduction (items 3–4), methods (items 5–15), results (items 16–17), discussion (items 18–20) and other (items 21–22).
Conclusions The BRIVAC checklist is the first initiative providing an operational checklist for improved reporting of qBRm 
applied to vaccines in scientific articles. It is intended to assist authors, peer-reviewers, editors and readers in their critical 
appraisal. Future initiatives are needed to provide methodological guidance to perform qBRm while taking into account the 
vaccine specificities.
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Key Points 
Although quantitative benefit-risk models (qBRm) 
applied to vaccines are increasingly used as an important 
tool to help decision makers with supporting benefit-
risk assessment, many publications on vaccine qBRm 
provide insufficient details on the methodological 
approaches used.
The aim of the present paper is to provide an operational 
checklist for improved reporting of vaccine qBRm in 
scientific articles: the consolidated standards of reporting 
quantitative Benefit-RIsk models applied to VACcines 
(BRIVAC) checklist.
The BRIVAC checklist is intended to (1) assist authors in 
adequately reporting qBRm methodologies and results, 
(2) support editors and peer reviewers when considering 
such articles for publication and (3) help readers in their 
critical appraisal.
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1 Introduction
Vaccination is among the most effective public health 
achievements for disease prevention and has led to a dra-
matic decline of several devastating diseases such as polio-
myelitis, diphtheria and smallpox [1]. Nevertheless, though 
generally well-tolerated, no vaccine can be considered abso-
lutely safe [2]. Vaccines differ from most of the other medic-
inal products in the sense that they can be administered to 
large populations, encompassing mostly healthy people, 
including children, and they can be introduced by health 
authorities as mandatory [3, 4]. In this context, understand-
ing the balance between the benefits and risks of vaccination 
is essential to ensure informed decision making [5]. Regula-
tory and public health authorities and pharmaceutical com-
panies are increasingly using quantitative benefit-risk mod-
els (qBRm) to support their benefit-risk assessment (BRA) 
[6–8]. qBRm integrate evidence from multiple sources to 
quantify and put into perspective the benefits and risks of a 
health intervention using mathematical formulae, statistical 
techniques or simulations [9]. A systematic review aiming 
at identifying and describing available qBRm applied to 
vaccines has been developed as the first of two companion 
papers [10]. This initial work highlighted the lack of formal 
structure used to conduct and report the results of qBRm, 
leading to a potential lack of transparency and reproduc-
ibility. In contrast, a growing number of regulators have 
provided guidance and references on structured frameworks 
for assessing the benefit–risk profile of drugs and devices 
[11–14]. Nevertheless, consensus about the reporting of 
qBRm, regardless of area, is yet to be achieved. This study 
proposes an operational checklist aiming at standardising the 
reporting of qBRm applied to vaccines and is the second of 
two companion papers.
2  Methods
The consolidated standards of reporting quantitative Ben-
efit-RIsk models applied to VACcines (BRIVAC) were 
designed as a checklist and based on multiple sources of 
information identified through a targeted literature search. 
These sources included (1) published documents provid-
ing recommendations on the conduct of qBRm applied to 
drugs [9, 12, 15–20] and to vaccines [21], (2) findings from 
a systematic literature review of qBRm applied to vaccines 
described in the first of two companion papers [10] and (3) 
guidelines on standards of reporting health research with 
a focus on observational studies (STROBE [STrengthen-
ing the Reporting of OBservational studies in Epidemiol-
ogy] and RECORD [REporting of studies Conducted using 
Observational Routinely-collected health Data]) [22–26] and 
economic evaluations (CHEERS [Consolidated Health Eco-
nomic Evaluation Reporting Standards]) [27].
To design the BRIVAC checklist, a preliminary list of 
items was created by one author (HA) by using these sources 
on study reporting, qBRm guidelines and vaccine specifici-
ties. The research team reviewed the items and established 
inclusion/exclusion status for each.
The BRIVAC statement provides guidance on key infor-
mation to report in scientific articles on vaccine qBRm: the 
assessed vaccines, the methodological choices made, the 
results and the interpretation. Each item is supported by (1) 
its definition, (2) a recommendation of what authors should 
report, (3) an explanation on the importance of its reporting 
and (4) an example to illustrate how they should be reported.
3  Results
The BRIVAC checklist consists of 22 items divided into six 
main sections corresponding to the classical subdivisions of 
a scientific publication: title and abstract (items 1–2), intro-
duction (items 3–4), methods (items 5–15), results (items 
16–17), discussion (items 18–20) and other (items 21–22). 
Both sections and items are listed in Table 1 and further 
described in the rest of this article.
3.1  Title and Abstract
3.1.1  Item 1: Title
Definition: The title captures the content and/or purpose of 
the research paper.
Recommendation: The authors should (1) clearly mention 
in the title that the publication focuses on the development 
of a ‘quantitative benefit-risk model’ and (2) identify the 
targeted vaccines. If applicable, the targeted geographical 
areas should be added.
Explanation: To date, studies on qBRm applied to vaccines 
have used a variety of non-harmonised terms to describe 
their quantitative benefit–risk approach (e.g. benefit risk, 
benefit harm, risk benefit). Knowing that electronic data-
bases use words in the title and abstract to yield search 
results, vague or ambiguous titles and abstracts might be 
inappropriately indexed [28]. A clear and precise title men-
tioning the type of analysis conducted and its scope will 
increase the likelihood of the publication being appropriately 
indexed.
Currently, no recognised terminology exists for publica-
tions focusing on qBRm. In this context, we propose sys-
tematically using in the publication’s title the ‘quantitative 
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Table 1  BRIVAC checklist: items to be included when reporting quantitative benefit–risk models applied to vaccines




 Title 1 Identify the work as a ‘quantitative benefit–risk model’, identify 
the vaccines of interest and, if applicable, the targeted geographi-
cal areas
□
 Abstract 2 Provide a structured summary of the background and objectives, 
methods (including the targeted population(s), geographical 
location and time frame of the qBRm, perspectives, alternatives, 
choice of benefit and risk outcomes, time horizon and choice of 




 Background 3 Provide an explicit statement of the relevant literature stressing the 
magnitude of the infectious disease burden and the benefit and 
risk outcomes of all health interventions available, the ration-
ale for conducting the analyses and the relevance of the study 
question. If the study was performed at the request of a specific 
stakeholder, this should be clearly stated
□




 Targeted populations 5 Define the targeted populations by describing their characteristics 
and the rationale for selection. If several populations or sub-
populations are targeted in the qBRm study, all of them should 
be reported
□
 Geographical location and time frame of the qBRm 6 Describe the geographical areas and the study period □
 Perspectives 7 Describe the perspectives involved in the analyses (analysis per-
formed at individual or population level, or both)
□
 Alternatives 8 Identify the alternatives compared with the vaccines of interest in 
the analyses and describe their relevance
□
 Choice of benefit and risk outcomes 9 Describe what outcomes were considered to define the benefits and 
risks of the vaccines of interest and the reasons to select these 
criteria. Specify measures (or unit) chosen to express benefit and 
risk outcomes. Providing a visual representation that displays the 
benefit and risk outcomes is strongly recommended
□
 Measurement and valuation of preference 10 If applicable, describe the preference-elicitation techniques used to 
weight benefit and risk outcomes as well as the size and charac-
teristics of the population from which the preference values were 
obtained
□
 Time horizons 11 Describe the relevant time horizons for the benefit and risk out-
comes evaluated and state why they are appropriate
□
 Discount rates 12 If applicable, report the use of discount rates for benefit and risk 
outcomes and mention why they are relevant
□
 Choice of model 13a Model type: Describe the type of model used (simulation or non-
simulation) and provide the rationale for its structure
□
13b Modelling attributes: Identify the key characteristics of the 
selected model, such as:
 Dynamic vs. static model
 Open vs. closed model
 Probabilistic vs. deterministic model
 Model integrating aggregated vs. individual-based data
 Waning effect vs. no waning effect
 Herd immunity vs. no herd immunity
□
 Analytical methods 14 Describe all analytical methods employed in the analyses, any data 
transformation conducted prior to the analyses and the analytical 
software used
□
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benefit-risk model’ terminology derived from the IMI-
PROTECT glossary [29]. First, the terminology ‘quantita-
tive’ ensures a clear differentiation from the ‘qualitative’ 
approach, based on descriptive templates or guidelines and 
relying on expert judgement only. Furthermore, authors need 
to identify in the title that the analysis targets to quantify 
‘benefit–risk’ balance. Finally, ‘model’ should be preferred 
as a generic term that encompasses any theoretical construct 
or analysis describing behaviours of a system. It is a term 
widely used across different disciplines [30].
Example: Quantitative benefit-risk model of the quadriva-
lent human papillomavirus vaccine for preventing anal can-
cer in males in Europe. (Hypothetical example).
3.1.2  Item 2: Abstract
Definition: The abstract is a short summary of the major 
aspects of the research paper.
Recommendation: The qBRm abstract should provide 
accurate and sufficiently detailed information on (1) the 
background and objectives, (2) the methods (including tar-
geted population[s], geographical location and time frame 
of the qBRm, perspectives from which the vaccine’s benefit 
and risk outcomes are evaluated, alternatives compared with 
the vaccines of interest, choice of benefit and risk outcomes, 
time horizon and choice of model, (3) the key results and (4) 
the conclusions (interpretation and generalisability).
Explanation: the abstract is used to help the readers quickly 
ascertain the paper’s purpose. A complete, structured and 
transparent abstract is important because most readers assess 
the relevance of a report or publication only on the basis of 
information provided in the abstract [31].
Example:
Background and Objectives: Meningococcal disease is 
an acute, serious illness caused by the bacterium Neisseria 
meningitidis. During 1995–2004, an estimated 1400–2800 
cases occurred in the USA annually. For the prevention of 
meningococcal disease, the Advisory Committee on Immu-
nization Practices (ACIP) recommends the conjugate vac-
cine ([MCV4] Sanofi Pasteur). Since the introduction of 
Table 1  (continued)
Section/item Item no. Recommendation Item has 
been 
reported
 Model input parameters 15 List all model input parameters feeding the model and provide 
their values, ranges, sources and criteria for selection. When 
probabilistic simulation models are used (see items 13a and 13b), 
the probability distribution used for each input parameter should 
also be described. Providing a tabular representation summaris-
ing this information is strongly recommended
□
Results
 Benefit and risk outcomes 16 Report measures, values and ranges resulting from the analyses to 
quantify the benefits and risks. Providing a visual representation 
summarising this information is strongly recommended
□
 Sensitivity/scenario analyses 17 If applicable, describe sensitivity and/or scenario analyses per-
formed to characterise uncertainty
□
Discussion
 Key results 18 Describe the key results in light of the study objectives □
 Limitations 19 Identify all the possible and relevant limitations of the model. 
Discuss the impact of these limitations on the findings
□
 Interpretation and generalisability 20 Provide an overall interpretation of the results considering similar 
analyses and other relevant evidence. Discuss the generalisability 
of the results and potentially suggest recommendations regarding 
the use of the vaccines assessed
□
Other
 Source of funding 21 Describe any sources of funding and the role of any funders in the 
study
□
 Conflicts of interest 22 Describe all relevant financial and non-financial relationships and 
activities and conflicts of interest that could be perceived as 
potentially influencing the submitted work
□
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MCV4 in 2005, a number of non-fatal Guillain-Barré syn-
drome (GBS) cases have been reported. The study evalu-
ates the benefits of MCV4 vaccination against the risk of 
vaccine-associated GBS.
Method: A simulation model was built simulating health 
events within a US cohort of 11-year-olds followed for 
8 years to assist decision makers in setting policy. Using a 
quantitative benefit–risk model comparing vaccination and 
no vaccination, we assess the trade-offs between the MCV4-
induced risks (GBS) and benefits (prevented meningococ-
cal disease). Incident meningococcal disease and GBS cases 
were modelled and quality-adjusted life-years (QALYs) cal-
culated as health outcome measures. Health utility indices 
were used in QALY calculations.
Key Results: Applying a 3% discount rate, MCV4 vaccina-
tion would save 2397 QALYs, whereas vaccine-attributable 
GBS could result in 5 QALYs lost.
Conclusions: Based on the result, MCV4 vaccination in the 
USA is strongly favoured despite possible vaccine-associ-
ated GBS risk. (Hypothetical example).
3.2  Introduction
3.2.1  Item 3: Background
Definition: The background section is a summary of topics 
most relevant to the BRA, allowing readers to understand 
the rationale and context of the study [32].
Recommendation: In the background section of publica-
tions on qBRm applied to vaccines, (1) relevant literature 
should be summarised, preferably stressing the magnitude 
of the infectious disease burden and all health interventions 
available with an outline regarding their benefit and risk 
outcomes; (2) the gap in the current knowledge and the rel-
evance of the study question should also be stated; (3) if the 
study was performed at the request of a specific stakeholder, 
this should be clearly stated. Potential stakeholders involved 
in the decision-making process encompass vaccine manufac-
turers, regulatory and public health authorities, healthcare 
providers and recipients of the candidate vaccine [33].
Explanation: The background section links the knowledge 
on the research topic and the reported qBRm. A well-written 
background section explains why the qBRm was performed 
and its added value to inform vaccination decision making 
[32].
Example:
The incidence of reported pertussis in the USA has been 
increasing steadily in the past 2 decades. This trend is occur-
ring despite the fact that childhood vaccination rates are at 
an all-time high and vaccine efficacy remains good. (…) 
However, several studies have suggested that immunity after 
vaccination wanes over time and protection may last only 
10–15 years, leading to a susceptible population around the 
time of mid-adolescence. (…) The morbidity associated with 
pertussis among adolescents and adults can be severe and its 
economic impact quite substantial, with significant time lost 
from school and work for these individuals.
Routine use of an effective vaccine among adolescents 
and adults might not only reduce morbidity rates in these 
age groups but also prevent infant pertussis infection through 
herd protection. However, the potential benefits of vacci-
nation need to be weighed against the possible problems. 
Vaccine adverse events, waning immunity after adolescent 
or adult vaccination and costs may all decrease the desir-
ability of routine pertussis vaccination in these age groups. 
We conducted this study to assist policy makers in decisions 
about whether and how pertussis vaccination of adolescents 
and/or adults should be adopted in the USA. (Example based 
on Lee et al. [34]).
3.2.2  Item 4: Objectives
Definition: The research objectives are a concise description 
of what the study is trying to achieve.
Recommendation: The final paragraph of the introduction 
should clearly list the study objectives in conjunction with 
BRIVAC checklist items 5–9 (i.e. the targeted population[s], 
the geographical location and the time frame of qBRm, the 
perspectives, the alternatives and the choice of benefit and 
risk outcomes) and 11 (i.e. time horizons), as described in 
the following.
Explanation: A precise formulation of the objectives allows 
justification of the appropriateness of the qBRm.
Example:
This study assessed risks (vaccine-associated GBS cases) 
and benefits (incident meningococcal disease cases) of 
MCV4 vaccination versus non-vaccination, on a US hypo-
thetical 11-year-old cohort enrolled in 2006 and followed 
over an 8-year period, to provide context to the Advisory 
Committee on Immunization Practices in making recom-
mendations to continue or discontinue the meningococcal 
vaccination programme. (Hypothetical example).
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3.3  Methods
3.3.1  Item 5: Targeted population(s)
Definition: The targeted population is the eligible population 
for which the qBRm was carried out.
Recommendation: The specific characteristics and the 
rationale for selection of the targeted population(s) should 
be precisely defined. If several populations or sub-popula-
tions are targeted in the qBRm study (e.g. neonates, infants, 
pregnant women, high-risk groups, elderly), they should all 
be reported.
Explanation: The choice of the targeted population(s) 
depends on the objectives of the study, the relevant literature 
stressing the vaccine benefit and risk outcomes, the infec-
tious disease epidemiology and the medical practices that 
could be driven by vaccine recommendations. One of the 
advantages of qBRm is that it enables the quantification of 
the benefit–risk balance for different targeted population(s) 
(e.g. universal vaccination or targeted risk groups only).
Since the quantitative benefit–risk balance of a vac-
cine might vary markedly depending on the population, it 
is crucial to define and justify the choice of the targeted 
population(s).
Example:
We analysed the hypothetical experience of a cohort of 1 
million children from birth to 6 years of age because virtu-
ally all pertussis mortality and severe morbidity occur in 
this age group and because most immunisation programmes 
do not recommend pertussis vaccination after the age of 
6 years. (Example based on Koplan et al. [35]).
3.3.2  Item 6: Geographical location and time frame 
of the qBRm
Definition: The geographical location defines where the 
study was performed (countries, states or regions), and the 
time frame defines the period when the study was performed.
Recommendation: Authors should describe the geographical 
areas and the study period.
Explanation: Infectious disease epidemiology (e.g. pathogen 
evolution, seasonal characteristics or disease severity), the 
population distribution and density, preventive and curative 
measures and healthcare systems may vary over time and 
across regions, and all these may directly affect the qBRm. 
It is therefore important to provide a clear description of the 
geographical location and time frame of the qBRm so that 
readers can assess the generalisability of the results.
Example:
To re-evaluate the risk–benefit profile of the Italian strat-
egy of hepatitis B vaccination. (…) To estimate the inci-
dence rates of hepatitis B, we used data of new acute infec-
tions notified in 1996 to the SEIEVA (the Italian surveillance 
of acute viral hepatitis). (Example based on Tosti et al. [36]).
3.3.3  Item 7: Perspectives
Definition: The study perspectives are the viewpoints from 
which the vaccine’s benefit and risk outcomes are evaluated.
Recommendation: The perspectives involved in the analy-
ses should be described (analysis performed at individual 
or population level, or both).
Explanation: In public health and disease prevention, a 
distinction should be made between the individual (benefit 
and risk for the candidate vaccine recipient only) and the 
population (positive and negative impacts for the whole 
population) perspectives [37]. For vaccines, both perspec-
tives are relevant when intending to conduct a qBRm, as 
the potential benefits and risks are not always borne by the 
same individual. For example, non-vaccinated individuals 
might benefit from vaccination while not being exposed to 
the risks induced by vaccination (i.e. indirect protection or 
herd immunity) [38, 39].
Furthermore, the benefit–risk decision could differ 
according the perspective used. For instance, when targeting 
disease eradication (e.g. measles, polio), the aim of vaccina-
tion is more to prevent disease re-emergence than to ensure 
individual protection [33].
Consequently, the results should be interpreted in light of 
the perspective chosen.
Example:
The model can be used to evaluate a person’s perspec-
tive of the risks and benefits of receiving a smallpox post-
exposure vaccination. I considered a person who has been 
exposed to somebody who may or may not have smallpox. 
(Example based on Meltzer [40]).
3.3.4  Item 8: Alternatives
Definition: The alternatives correspond to all options to be 
evaluated against the main intervention of interest.
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Recommendation: The alternatives compared with the vac-
cines of interest in the analyses should be described, as well 
as their relevance.
Explanation: qBRm are never made on an absolute scale 
but are relative to a reference scale. The targeted vaccines 
need to be compared with alternatives such as the absence 
of vaccination, other vaccines, other preventive measures 
(e.g. human papillomavirus [HPV] screening vs. HPV vac-
cination), alternative indications (e.g. different vaccination 
schedules for the targeted vaccines) and alternative policies 
for the implementation of the vaccination programmes (e.g. 
recommended vs. mandatory implementation) [33]. The 
qBRm results and their interpretation are directly impacted 
by the comparator chosen.
Example:
The three strategies involved either (1) vaccinating all 
infants at 12 months of age, (2) delaying vaccination until 
10 years of age and then vaccinating only if a child has no 
history of varicella or (3) not vaccinating at all. (Example 
based on Rothberg et al. [41]).
3.3.5  Item 9: Choice of benefit and risk outcomes
Definition: The choice of outcomes corresponds to criteria 
considered to define the benefits and risks of the vaccine of 
interest.
Recommendation: The authors should detail (1) the choice 
of criteria to estimate benefit and risk outcomes, (2) the rea-
sons to select these criteria and (3) the specific measures 
(or unit) chosen to express benefit and risk outcomes. Fur-
thermore, providing a visual representation that displays the 
benefit and risk outcomes is strongly recommended.
Explanation: The benefit outcomes represent protective 
effects of vaccination against an infectious disease and com-
plications. There are different ways to express the vaccine 
benefits: efficacy (direct effect of vaccination measured in 
pre-licensure randomised controlled trials, where vaccina-
tion is allocated in optimal conditions), effectiveness (direct, 
indirect, total or global effects of vaccination measured in 
routine) or impact (the proportionate reduction in disease 
burden, comparing incidences between a pre-vaccine and a 
post-vaccine period in the same population) [42, 43]. Risk 
outcomes represent adverse events following immunisation 
(AEFI). Reported AEFI can either be true adverse reactions 
(i.e. resulting from the vaccine or immunisation process) 
or coincidental events that are not due to the vaccine or 
immunisation process but are temporally associated with 
immunisation. Consequently, the causal association between 
the event and vaccination should be defined.
Furthermore, a huge diversity of measures to express ben-
efits and risks are available. Measures used in qBRm might 
include, but are not limited to, measures expressed in natural 
units (e.g. impact numbers, number needed to harm or vacci-
nate [NNH or NNV], life-years gained) or composite health 
measures based on preferences for health (e.g. quality-
adjusted life-years [QALYs], disability-adjusted life-years 
[DALYs] or healthy life expectancy [HALE]). Measures 
used in qBRm are summarised elsewhere [9, 11, 16, 19, 20] 
and can be divided into single and trade-off indices. Single 
indices use measures to quantify benefit and risk outcomes 
separately, whereas trade-off indices integrate benefit and 
risk outcomes into a composite measure index allowing a 
direct interpretation of the benefit–risk balance [10].
Considering the existing classification of benefit and risk 
outcomes and the diversity of measures to express it, it is 
crucial to precisely describe all the outcomes considered in 
the qBRm and the measures used to leverage the relevance 
of qBRm findings. The visual representation is a helpful tool 
to clearly present all benefit and risk outcomes considered.
Example:
We conducted a risk–benefit analysis using published 
rotavirus and intussusception epidemiologic data to model 
the impact of a vaccination programme with either 20 or 
90% coverage scenarios compared with no vaccination pro-
gramme. Based on the methodology of Patel et al. 2011, 
we used a birth cohort in 2005 to estimate the number of 
hospitalisations attributable to rotavirus that could poten-
tially be prevented and the number of excess intussuscep-
tion hospitalisations that could be caused by the vaccination. 
We also calculated the number of infants who would need 
to be vaccinated to prevent one rotavirus hospitalisation or 
cause one excess intussusception hospitalisation. Because 
rotavirus and intussusception mortality is negligible in Sin-
gapore, we analysed hospitalisation as our outcome of inter-
est. (Example based on Yung et al. [44]).
3.3.6  Item 10: Measurement and valuation of preference
Definition: The health state preference values (also called 
utilities) are used to represent the strength of individuals’ 
preferences for different health states. Several preference-
elicitation techniques (e.g. time trade-off approach, standard 
gamble approach or discrete choice experiment) can be used 
to obtain health state preference values [45].
Recommendation: When applicable, authors should describe 
(1) techniques used to weigh benefit and risk outcomes and 
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(2) the size and characteristics of the population from which 
the preference values were obtained.
Explanation: Composite health measures (see item 9) com-
bine different health outcomes (morbidity and mortality) 
into a single commensurable score by using techniques to 
determine preference values.
It is critical to describe the population from which prefer-
ence values were obtained because they may differ depend-
ing on respondents (e.g. general population, candidate vac-
cine recipients, parents, healthcare providers or experts) 
[46–51]. For some vaccines (e.g. travellers’ vaccines), both 
the potential benefits and risks are borne by the same indi-
vidual. Hence, preference values from candidate vaccine 
recipients are informative. For vaccination programmes 
aiming at reducing disease transmission within the general 
population, one might argue that the general population and/
or public health experts play an important role in generating 
these preference values. For vaccines administered to young 
children, the vaccination decision usually falls to the child’s 
parents and hence, parent’s preferences are informative.
Example:
To estimate a utility value for the state of permanent neu-
rological sequelae following tuberculous meningitis, sub-
jects were recruited to participate in an interview involving 
the standard gamble technique. During the interview, sub-
jects were offered two alternatives: the first was the pos-
sibility of perfect health for the rest of the life with a prob-
ability of immediate death, and the second was living the 
rest of the life with permanent sequelae from tuberculous 
meningitis. (…) Volunteers for interviews were recruited 
from three groups: first-year medical students at the Univer-
sity of Ottawa (year of entrance 2002); employees at Health 
Canada; and staff at the Department of Social Development 
and Health, Mohawk Council of Akwesasne. (…) A total of 
107 subjects were interviewed in the survey. (Example based 
on Clark and Cameron [52]).
3.3.7  Item 11: Time horizons
Definition: The time horizon refers to the duration over 
which benefit and risk outcomes are evaluated.
Recommendation: For all benefit and risk outcomes, it is 
important to mention and provide the rationale for the appro-
priateness of the selected time horizons.
Explanation: Lifetime horizon can be used as a first instance. 
Nevertheless, a shorter time horizon may be used when it 
is demonstrated that all relevant outcomes are captured. For 
vaccines, the time horizon is based on the nature of the ill-
ness (e.g. seasonal for influenza, lifetime for rubella), the 
vaccine characteristics (e.g. waning effect) and the policies 
by which the vaccine is administered (e.g. age of vaccina-
tion). Therefore, qBRm applied to vaccines will be particu-
larly sensitive to the choice of the time horizons [53].
Example:
Although it has been recommended elsewhere that a life-
time horizon be considered in such studies, our model fol-
lowed a theoretical cohort from birth to the age of 14 years. 
This approach was chosen for consistency with earlier mod-
elling studies on BCG and because current evidence suggests 
BCG protection lasts perhaps 10–15 years. Although the 
prevention of childhood TB and disseminated BCG infec-
tion have long-term benefits in terms of life-years gained, 
BCG does not impact on any TB-related risk in adulthood 
and, as such, has no impact on outcomes beyond the age of 
15 years, or as described above, the risk of morbidity and 
mortality in the population. Most importantly, the lifetime 
horizon approach would not have affected the most impor-
tant outcome in the model, namely those threshold values 
for severe combined immunodeficiency (SCID) incidence, 
which alter the decision to use BCG for a given risk of tuber-
culous infection in the population. (Example based on Clark 
and Cameron [52]).
3.3.8  Item 12: Discount rates
Definition: The discount rates are used to reduce the value 
of benefit and risk outcomes over time.
Recommendation: If discount rates are used, they should be 
mentioned and their relevance justified.
Explanation: The benefit and risk outcomes may occur at 
different points in time, present or future. This is particularly 
true of vaccination benefits (protection against an infectious 
disease) that may appear in the far future while some adverse 
events could be identified early after vaccination and vice 
versa. Sometimes, vaccination benefits and risks may even 
impact on future generations. However, outcomes that are 
predicted to occur in the future might be valued less than 
those predicted to occur in the present by applying discount 
rates. Discount rates are not universal and will vary in dif-
ferent settings [54]. Discounting schemes applicable to vac-
cines are presented by Jit and Mibei [55]. Consequently, 
it is important to report discount rates because benefit and 
risk outcomes, specifically those in the far future, may be 
particularly sensitive to the choice of the discount rates [45].
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Example:
To compare health outcomes occurring in different time 
periods, we discounted health outcomes to the present value. 
A discount rate of 3% was applied to health outcomes from 
GBS and those from meningococcal disease as suggested in 
the literature. (Example based on Cho et al. [56]).
3.3.9  Item 13: Choice of model
Item 13a: Model type
Definition: The model is an umbrella term that encompasses 
any theoretical construct describing behaviours of a system, 
and it is widely used across different disciplines [30].
Recommendation: The research paper should describe the 
type of the model used for the analyses (simulation or non-
simulation) and provide the rationale for its structure.
Explanation: The choice of the model type depends on several 
considerations such as the analyst’s technical skills, the required 
model complexity, the question at hand and the nature of the 
decision problem, the natural history and features of the par-
ticular infectious disease of interest and the data available to 
parameterise and calibrate the model [57, 58]. qBRm can be 
categorised into simulation and non-simulation models. In the 
first, benefit and risk outcomes are derived from simulation 
techniques of various degrees of complexity including as many 
components and interaction as possible (e.g. Markov model, 
microsimulation or dynamic transmission models) [59]. Non-
simulation models are based on a simple calculation, mathe-
matical function or statistical model [30]. Transparent and clear 
communication of the model type is of importance for readers 
to assess and/or reproduce the model results.
Example:
We adapted an age-structured disease transmission model 
and added an influenza vaccination adoption function mod-
elled as a Bass diffusion process while assuming a univer-
sal vaccination policy. Bass diffusion models are commonly 
used in the marketing literature to describe the diffusion of 
innovations. (…) a detailed description of the model is in S1 
File. (Example based on Maro et al. [60]).
Item 13b: Modelling attributes
Definition: The modelling attributes are key dimensions in 
describing the approaches used in qBRm.
Recommendation: The modelling characteristics should 
be clearly reported according to the following dichoto-
mous attributes based on the classification defined by Kim 
and Goldie [30]: (1) Dynamic versus static model: force 
of infection is assumed to change over time (dynamic) or 
not (static); (2) Open versus closed model: individuals are 
tracked in the model and allowed to enter and exit the cohort 
(open) or not (closed); (3) Probabilistic versus determinis-
tic model: the uncertainty around the input parameters is 
taken into account (probabilistic) or not (deterministic); (4) 
Model integrating aggregated versus individual-based data: 
the population’s behaviour in the model is simulated using 
aggregate variables of which values are population averages 
(aggregated data) or the behaviours of individuals in the 
population are tracked (individual-based data); (5) Waning 
effect consideration versus no waning effect consideration: 
vaccine efficacy/effectiveness decreases with time or not; 
(6) Herd immunity consideration versus no herd immunity 
consideration.
Explanation: It is important to stress that, unlike other medi-
cines, herd immunity (i.e. protection of individuals who are 
not immunised against an infectious disease while a large 
proportion of the whole population is immunised against 
that infectious disease) is a unique attribute of vaccines, 
and its incorporation or not in the model should be men-
tioned and discussed. An example of vaccination strategy 
that exploits the herd immunity is the cocooning (i.e. vac-
cination of parents and family members against infectious 
diseases to protect infants who are too young to get vacci-
nated themselves).
A clear description of modelling attributes facilitates the 
understanding and assessment of the model type and tech-
niques used.
Example:
We simulated a closed static cohort of 4.3 million adop-
ters of influenza vaccination using aggregated data from the 
PRISM system database. We did not take into consideration 
the induced herd protection, and a sigmoid (reverse S) shape 
curve was fitted to year 1 and year 2 efficacy to account for 
waning of protection with time post-vaccination. Credible 
intervals around the benefit–risk ratios and differences were 
calculated based on probabilistic uncertainty analyses and 
Monte Carlo simulations. (Hypothetical example).
3.3.10  Item 14: Analytical methods
Definition: The analytical methods are statistical techniques 
supporting the evaluation.
Recommendation: The general principle is to report (1) all 
the analytical methods employed, (2) any data transforma-
tion conducted prior to the analysis and (3) the analytical 
software used.
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Explanation: The methods used depend on the qBRm 
design. This can include methods for dealing with cen-
sored, skewed or missing data; methods for pooling data; 
approaches to validate or make adjustments to a model; 
extrapolation methods; and methods for handling popula-
tion heterogeneity and uncertainty [27]. To judge the reli-
ability, appropriateness and validity of the methods and 
related qBRm results, the analytic strategy used should be 
fully reported. The guiding principle of reporting statistical 
analyses is to describe analytical methods in a detailed and 
clear enough manner to enable knowledgeable readers with 
access to the original data to reproduce the reported findings.
Example:
The analysis included only case patients (and controls, 
for the case–control analysis) for whom vaccination records 
were available on the Australian Childhood Immunisation 
Register (ACIR). The combined data set included all 282 
cases from the state-based admissions data plus another 38 
captured by Paediatric Active Enhanced Disease Surveil-
lance (PAEDS). In the eight cases of patients with incom-
plete records, the ACIR documented receipt of a second (or 
third) dose of rotavirus vaccine but data were missing for 
the earlier dose(s) (…) Analysis was performed using Stata 
11.2 software (StataCorp; 2009). (…) Results (obtained 
from a conditional Poisson regression model) are reported 
as relative incidence (RI), with 95% confidence intervals 
(CIs), for each exposure period compared with time outside 
this window. (…) Alternative approaches to the method of 
age adjustment, which varied the age categorisation and 
smoothed the age effect, were explored in sensitivity analy-
ses. (…) The annual average number of ICD-coded intus-
susception cases was 240; adjustment by a factor of 0.6 has 
been made to estimate the proportion of Brighton level 1 
cases. (Example based on Carlin et al. [61]).
3.3.11  Item 15: Model input parameters
Definition: The model input parameters are all evidence 
combined into the model for the benefit–risk estimates.
Recommendation: Authors should list (1) all input param-
eters used in the analyses, (2) their values, (3) their ranges 
and (4) their sources, with the appropriate references and 
(5) the criteria for selection. When probabilistic simulation 
models are used (see items 13a and 13b), (6) the probability 
distribution used for each input parameter should also be 
described. A tabular representation summarising these ele-
ments is strongly recommended.
Explanation: To conduct a qBRm, authors should identify 
and combine available data that allowed feeding the input 
parameters. Those data are rarely extractable from a single 
study and are usually collected from diverse sources, includ-
ing clinical trials, observational studies, administrative data-
bases, case-series, expert opinion, assumptions from authors 
and/or secondary analyses (e.g. meta-analysis) [62]. Unlike 
other medicines, vaccine model input parameters will more 
often rely on post-authorisation data to characterise the risks 
and potentially the effectiveness. Indeed, the occurrence of 
some AEFI is rare. Moreover, for most vaccines, long-term 
protection is expected, and that cannot be fully investigated 
using pre-authorisation studies following-up small cohorts, 
during a limited time period [2, 63]. Furthermore, qBRm 
applied to vaccines can require specific input parameters, 
including those necessary to consider transmission dynam-
ics, heterogeneity in contact patterns and policy for the vac-
cination programme.
As with any model, the results obtained with qBRm 
depend on the quality of the data inputs, the methods used 
to derive these (see item 14) and the suitability of the model 
structure (see items 13a and 13b). Model input parameters 
should therefore be clearly documented and justified to 
ensure transparency, to allow readers to assess the validity 
of the model and to facilitate its reproducibility. A tabular 
representation is a helpful tool to clearly present all model 
input parameters considered.
Example:
All parameters included in the benefit–risk analysis and 
their random distributions are listed in Table 1. (Example 
based on Ledent et al. [64]).
3.4  Results
3.4.1  Item 16: Benefit and risk outcomes
Definition: The benefit and risk outcomes are the results 
obtained from the analyses.
Recommendation: For each alternative, the measures, values 
and ranges of benefit and risk outcomes should be reported. 
Providing a visual representation summarising this informa-
tion is strongly recommended.
Explanation: The outcomes should be explicitly described in 
order not to bias reader interpretation. The use of appropriate 
visual representation (e.g. table, scatter plot, line graph, bar 
chart/graph) can support qBRm assessment and constitute 
a key support for communicating the qBRm findings [16].
It is even more important considering that results derived 
from qBRm are used by various stakeholders to assess and 
compare the benefit–risk balance for different strategies of 
interest and can support decision making.
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Example:
In the absence of a rotavirus vaccine program in France, 
we estimated a median incidence of 15,059 (95% CI 
12,100–18,476) rotavirus gastroenteritis (RVGE) hospitali-
sations and 10.13 (95% CI 4.64–19.46) RVGE deaths for an 
average French birth cohort of 791,183 children followed 
from birth to 5 years of age. Within the same cohort, we esti-
mated an annual number of 323 (95% CI 257–400) intussus-
ception hospitalisations and 0.45 (95% CI 0.19–0.88) intus-
susception deaths in infants below 1 year of age. (…) The 
results following vaccination with two doses of Rotarix are 
presented in Table 2. We estimated that vaccination would 
prevent approximately 75% of all RVGE hospitalisations 
and deaths in the total number of French children below 
5 years of age, leading to a reduction of 11,132 (95% CI 
7842–14,408) hospitalisations and 7.43 (95% CI 3.27–14.68) 
deaths. We also estimated that vaccination would cause 6.86 
(95% CI 2.25–38.37) intussusception hospitalisations and 
0.0099 (95% CI 0.0024–0.060) intussusception deaths in one 
French birth cohort of infants below 1 year of age. (…) The 
Rotarix benefit–risk ratio for hospitalisation is 1624 (95% CI 
240–5243) for children below 5 years of age (Table 2) (…) 
Similarly, for each intussusception death caused, 743 (95% 
CI 93–3723) RVGE deaths would be prevented by vaccina-
tion. (Example based on Ledent et al. [65]).
3.4.2  Item 17: Sensitivity/scenario analyses
Definition: The sensitivity and scenario analyses are used to 
explore the effects of uncertainty on the results by varying 
the value(s) of one (or more) key parameter(s).
Recommendation: If applicable, the authors should describe 
the sensitivity and/or scenario analyses performed to charac-
terise the degree of uncertainty in the analyses.
Explanation: Various sources of uncertainty must be consid-
ered in qBRm, such as statistical uncertainty, management 
and quality of the data sources, implications of missing data, 
etc. Furthermore, vaccines require consideration of addi-
tional uncertainties such as the disease transmission factor, 
as well as the uncertainties related to vaccine policy and 
acceptance by individuals.
However, one of the methodological strengths of model-
ling is the possibility to challenge the robustness of its result 
and to quantify the range of uncertainty through sensitivity/
scenario analyses [66]. Sensitivity analyses evaluate how 
the uncertainty of model inputs affect the model outcomes. 
Sensitivity analyses can be categorised as deterministic 
(‘one-way’ or ‘multiple-way’) or probabilistic [45]. In sce-
nario (or ‘what-if’) analyses, different epidemiological or 
healthcare scenarios of interest are investigated (such as 
different population coverages, different ages at vaccination 
or different background incidence rates). In addition, authors 
can also assess the evolution of the benefit–risk results in the 
future, based on plausible scenarios relying on retrospective 
data and other assumptions [55].
Example:
Deterministic central estimates (i.e. best estimates for 
each input parameter) and probabilistic 95% uncertainty 
intervals (UIs) were calculated for 11 age-restricted sched-
ules and 18 age-unrestricted schedules. All input parameters 
and their distributions are shown in the appendix. Central 
estimates were also calculated for six what-if scenarios: rel-
ative risks (RRs) of intussusception varying with under-5 
mortality (figure, appendix p 12); double the RR of intussus-
ception for the first dose when given after 15 weeks of age; 
vaccine efficacy and waning equivalent to low mortality set-
tings; less rapid waning efficacy (based on a power function 
described in detail elsewhere); less rapid waning efficacy for 
all primary doses administered as part of a neonatal schedule 
(appendix p 14); and pessimistic access to hospital for intus-
susception cases (based on the proportion of children who 
could reach a public hospital within 2 h). (Example based 
on Clark et al. [67]).
3.5  Discussion
3.5.1  Item 18: Key results
Definition: The key results section summarises the main 
findings derived from the analyses with reference to study 
objectives.
Recommendation: The discussion should include a succinct 
and objective summary of the key results and should refer 
to the objectives listed in the introduction.
Explanation: A clear summary of key results will help read-
ers assess whether the authors’ interpretation (see item 20) 
is supported by the results of the model or not.
Example:
This study quantified and compared the risk of menin-
gococcal conjugate vaccine-associated GBS with the risks 
and benefits of no versus full immunisation of a cohort of 
11-year olds. We found that the benefits of MCV4 vaccina-
tion substantially exceeded the risks of MCV4-associated 
GBS when measured by cases, deaths, and QALYs. The 
occurrence of death or long-term disability in up to one-
third of meningococcal disease cases as well as the burden 
of disease caused by serogroups covered by the vaccine con-
trast with the small and time-limited risk of GBS following 
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vaccination. Further, the decision analysis continues to 
strongly favour the vaccination program at risks three times 
those observed in post-licensure surveillance. Also, even at 
lower meningococcal disease incidence rates, QALYs saved 
by vaccination are greater than QALYs lost due to vaccine-
associated GBS. (Example based on Cho and Clark [56]).
3.5.2  Item 19: Limitations
Definition: The limitations section covers the weaknesses of 
the analyses and assesses their potential impact on the study 
results and the interpretation thereof.
Recommendation: The authors should identify and discuss 
all the relevant limitations of the model and their impacts 
on the findings.
Explanation: The discussion on limitations provides the 
readers with potential sources of bias and/or lack of pre-
cision. A clear presentation of limitations strengthens the 
study conclusions and the generalisability of the findings. 
qBRm applied to vaccines often implies several simplifying 
assumptions and methodological choices (e.g. time horizon, 
alternatives, modelling approach). For this reason, it is cru-
cial to identify and discuss the related potential limitations 
of the model as well as their possible effects on the estimated 
benefit–risk balance.
Example:
The model was limited in scope, with its exclusive focus 
on death and life-debilitating effects caused by the pandemic 
influenza and by the vaccine, respectively. All considera-
tions of non–life-threatening morbidity, hospitalisations and 
other outcomes were not considered, nor were other popula-
tions, such as children and pregnant women, explicitly taken 
into account. The model is further based on the assumption 
that vaccination after approval occurs in a timely and broad 
manner, which does not happen in reality because of dif-
ferences in vaccine supply and geographical and seasonal 
differences between healthcare environments. However, even 
if this were to be taken into account, it is unlikely to change 
the resulting preference for the earlier decision. (Example 
based on Phillips et al. [68]).
3.5.3  Item 20: Interpretation and generalisability
Definition: The interpretation and generalisability section 
contextualises the main findings by comparing them with 
previous work and discussing the external validity of the 
study results.
Recommendation: The authors should provide an over-
all interpretation of the results, considering similar analy-
ses and other relevant evidence. They should discuss the 
generalisability of the results and potentially suggest rec-
ommendations regarding the use of the assessed vaccines.
Explanation: This part of the discussion is crucial to 
objectively compare qBRm with other studies available in 
the literature and provide explanation in case of discrepan-
cies. Importantly, it helps readers understand and appreciate 
the added value of the study to the existing literature [27]. 
The authors should also discuss the potential generalisability 
of their results to other populations and geographical set-
tings and suggest recommendations regarding the use of the 
assessed vaccines based on results of the model.
Example (interpretation):
A study in the USA estimated the prevention of 1093 
rotavirus admissions for each additional intussusception 
admission, closer to our estimate of 1360 averted rotavirus 
hospitalisations per excess intussusception case under the 
current age restrictions. In France, it was reported that for 
every intussusception hospitalisation and every intussuscep-
tion death caused by vaccination, 1624 rotavirus hospitalisa-
tions and 743 deaths were prevented by vaccination, respec-
tively. (Example based on Bruun et al. [69]).
Example (generalisability):
Through the model, we have assumed a homogene-
ous annual risk of infection throughout the population at 
a national level. However, it is clear from current notifi-
cation data that cases are often concentrated in high-risk 
populations. It is therefore likely that the risk of infection 
in such sub-population well exceeds the calculated average. 
Given the above limits, this model nevertheless provides 
good estimates when compared with surveillance data from 
France and Italy and it could represent a valid tool to start a 
decision-making process on BCG vaccination in European 
countries. (Example based on Manissero et al. [70]).
3.6  Other
3.6.1  Item 21: Source of funding
Definition: The source of funding section reports resources 
received (directly or indirectly) to enable the completion of 
the work.
Recommendation: The authors should report all sources 
of funding and the role of each funder, if any, in the different 
steps of the research conduct (e.g. design, data collection, 
analysis, drafting of the manuscript, decision to publish). 
Depending on individual journal policies, source of fund-
ing and the contributions of each funder may be listed in an 
‘Acknowledgements’ section.
Explanation: The funding can come from various 
sources, including research councils, charities, governing 
bodies and industry. Public trust in the scientific work and 
the credibility of published articles depends in part on how 
transparently an author’s relationships and activities, directly 
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or topically related to a work, are handled during the scien-
tific process. Consequently, to prevent any controversy and 
vaccine hesitancy, it is crucial that authors of publications 
of qBRm applied to vaccines report all sources of funding.
Example:
This work was carried out with the aid of a grant from 
the International Development Research Centre (IDRC), 
Ottawa, Canada, as part of the Canadian International Immu-
nization Initiative Phase 2 (CIII2). This initiative is a project 
of the Global Health Research Initiative (GHRI). The views 
expressed are those of the authors and do not necessarily 
reflect the views of IDRC. (Example based on Ledogar et al. 
[71]).
3.6.2  Item 22: Conflicts of interest
Definition: The conflicts of interest section describes situ-
ations where the impartiality of research may be compro-
mised because the researcher stands to profit in some way 
from the conclusions they draw [72].
Recommendation: The authors should report any financial 
and non-financial relationships and activities and conflicts of 
interest that could be perceived as potentially influencing the 
submitted work. In the absence of a journal policy, authors 
should refer to the International Committee of Medical Jour-
nal Editors [73].
Explanation: As for the source of funding, disclosing 
any financial and non-financial relationships and activities 
and conflicts of interest ensures compliance with rules and 
public trust.
Exmple:
KT received personal fees from the GSK group of com-
panies, Pfizer, and Merck Sharp & Dohme unrelated to this 
work. The other authors have no conflicts of interest. (Exam-
ple based on Yung et al. [44]).
4  Discussion
As qBRm is increasingly used in vaccinology, developing 
standards for reporting the methods and results is key to 
ensure a transparent disclosure of the analysis and its repro-
ducibility, thereby facilitating interpretation of the study 
results and comparison with existing literature. To the best 
of our knowledge, the BRIVAC statement is the first oper-
ational checklist aiming at standardising the reporting of 
qBRm.
Adequate reporting should allow identification of the 
strengths and weaknesses of a modelling exercise and pro-
vide a valuable basis for decision and communication about 
vaccine benefit–risk profiles [74]. Consequently, BRIVAC 
is intended to (1) assist authors in adequately reporting 
methodologies and results of qBRm applied to vaccines, (2) 
support editors and peer reviewers when considering such 
articles for publication and (3) help readers in their critical 
appraisal.
A statement such as BRIVAC should not be interpreted 
as an attempt to confine the conduct of qBRm applied to 
vaccines in a rigid format. Its objective is to ensure that 
methodological choices are adequately disclosed. The BRI-
VAC checklist can be used to assess the quality of qBRm 
reporting but not of its conduct.
Detailed guidance on choice of methods in vaccine qBRm 
has not yet been achieved and is currently lacking [7]. Future 
initiatives should be launched to develop methodological 
guidance to perform qBRm taking vaccine specificities 
into account. The present series of papers, findings from 
the Accelerated Development of Vaccine Benefit-Risk Col-
laboration in Europe (ADVANCE) project [21, 75, 76] and 
health technology assessment methods should support the 
development of such guidelines [77].
There may be some limitations to the present approach. 
First, the BRIVAC checklist assumes that the information 
required for adequate reporting does not exceed the con-
ventional space limits of some scientific journals. If this is 
not the case, we recommend using online appendices (when 
available) to provide an extended description of the meth-
odological approaches used.
In addition, the BRIVAC’s contributors were not rep-
resentative in terms of geography (over-representation of 
European researchers), research interests and disciplines. 
However, we believe that this checklist will serve as a start-
ing point to improve the reporting of vaccine qBRm. The 
next steps in updating and validating the BRIVAC checklist 
will include using a large Delphi panel with a multidiscipli-
nary team of editors and content experts in BRA, vaccines, 
infectious diseases and reporting and representatives from 
academia, clinical practice, industry, and government.
To enable the validation, dissemination and routine 
implementation of the BRIVAC checklist, the reporting 
guidance could be integrated in the EQUATOR (Enhanc-
ing the Quality and Transparency of Health Research) 
network [74], which is an international initiative set up to 
help improve the reliability and value of health literature 
by promoting responsible reporting of health research. The 
EQUATOR website offers an up-to-date centralised resource 
compiling most reporting guidance related to health research 
[78].
5  Conclusion
The BRIVAC statement is an operational checklist for 
improving the reporting of qBRm applied to vaccines in 
scientific articles. Its aim is to ensure that methodologi-
cal choices and results are adequately disclosed to ensure 
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transparent and reproducible analyses, thereby facilitating 
study result interpretation and comparability. The BRIVAC 
checklist is the first initiative aiming at structuring and har-
monising vaccine qBRm reporting. Future initiatives are 
needed to validate BRIVAC on a large scale and to provide 
methodological guidance to perform qBRm taking vaccine 
specificities into account.
Acknowledgements The authors would like to thank Sophie Timmery 
and Salomé Murinello (Modis, Wavre, Belgium) for editorial assistance 
and coordination on behalf of GSK (Rixensart, Belgium).
Declarations 
Funding This study is part of a PhD programme funded by GlaxoS-
mithKline Biologicals SA and the ANRT (Association Nationale pour 
la Recherche et la Technologie, Paris, France).
Conflict of interest Hugo Arlegui was employed by the GSK group 
of companies at the time of the study, in the framework of a PhD pro-
gramme. Vincent Bauchau, Gaëlle Nachbaur and Nicolas Praet are 
employed by the GSK group of companies. Vincent Bauchau, Gaëlle 
Nachbaur and Nicolas Praet also hold shares in the GSK group of com-
panies. Kaatje Bollaerts and Bernard Bégaud have no conflicts of inter-
est that are directly relevant to the content of this article.
Ethics approval Not applicable.
Consent to participate Not applicable.
Consent for publication Not applicable.
Availability of data and material Data sharing is not applicable to this 
article as no datasets were generated or analyzed during the current 
study.
Code availability Not applicable.
Authors’ contribution All authors attest they meet the ICMJE criteria 
for authorship. All authors were involved in the conception of the study. 
Hugo Arlegui participated in the collection and generation of the study 
data. Hugo Arlegui performed the study. All authors were involved 
in the analyses and interpretation of the data. All authors revised the 
manuscript critically for important intellectual content and gave final 
approval to submit for publication.
Open Access This article is licensed under a Creative Commons Attri-
bution-NonCommercial 4.0 International License, which permits any 
non-commercial use, sharing, adaptation, distribution and reproduction 
in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Com-
mons licence, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative 
Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons 
licence and your intended use is not permitted by statutory regula-
tion or exceeds the permitted use, you will need to obtain permission 
directly from the copyright holder. To view a copy of this licence, visit 
http://creat iveco mmons .org/licen ses/by-nc/4.0/.
References
 1. WHO. Immunization. World Health Organization; 2017. https ://
www.who.int/topic s/immun izati on/en/. Accessed 13 Mar 2020.
 2. Chen RT, Glanz JM, Vellozzi C. Pharmacoepidemiologic stud-
ies of vaccine safety. In: Brian LS, Stephen EK, Sean H, editors. 
Pharmacoepidemiology, 5th edn. Wiley; 2012. p. 423–68. 
 3. European Medicines Agency (EMA). Guideline on good phar-
macovigilance practives (GVP). Vaccines for prophylaxis against 
infectious diseases. 2013. https ://www.ema.europ a.eu/docs/en_
GB/docum ent_libra ry/Scien tific _guide line/2013/12/WC500 15783 
9.pdf. Accessed 13 Mar 2020.
 4. Larson HJ, Cooper LZ, Eskola J, Katz SL, Ratzan S. Address-
ing the vaccine confidence gap. Lancet. 2011;378(9790):526–35. 
https ://doi.org/10.1016/S0140 -6736(11)60678 -8.
 5. Parashar UD, Cortese MM, Payne DC, Lopman B, Yen C, Tate 
JE. Value of post-licensure data on benefits and risks of vaccina-
tion to inform vaccine policy: the example of rotavirus vaccines. 
Am J Prev Med. 2015;49(6 Suppl 4):S377–S382382. https ://doi.
org/10.1016/j.amepr e.2015.09.005.
 6. Bonhoeffer J, Black S, Izurieta H, Zuber P, Sturkenboom M. 
Current status and future directions of post-marketing vac-
cine safety monitoring with focus on USA and Europe. Bio-
logicals. 2012;40(5):393–7. https ://doi.org/10.1016/j.biolo gical 
s.2012.07.007.
 7. Greenberg M, Simondon F, Saadatian-Elahi M. Perspectives on 
benefit-risk decision-making in vaccinology: conference report. 
Hum Vaccines Immunother. 2016;12(1):176–81. https ://doi.
org/10.1080/21645 515.2015.10756 79.
 8. Schosser R. Risk/benefit evaluation of drugs: The role of the 
pharmaceutical industry in Germany. Eur Surg Res. 2002;34(1–
2):203–7. https ://doi.org/10.1159/00004 8910.
 9. Mt-Isa S, Hallgreen CE, Wang N, Callreus T, Genov G, Hirsch I, 
et al. Balancing benefit and risk of medicines: a systematic review 
and classification of available methodologies. Pharmacoepidemiol 
Drug Saf. 2014;23(7):667–78. https ://doi.org/10.1002/pds.3636.
 10. Arlegui H, Bollaerts K, Salvo F, Bauchau V, Nachbaur G, Begaud 
B, et al. Benefit-risk assessment of vaccines. Part I: a systematic 
review of quantitative benefit-risk models applied to vaccines. 
Drug Saf. 2020. https ://doi.org/10.1007/s4026 4-020-00984 -7.
 11. Pharmacoepidemiological Research on Outcomes of Therapeutics 
by a European Consortium (PROTECT) Benefit Risk website. 
https ://www.prote ctben efitr isk.eu/index .html. Accessed 13 Mar 
2020.
 12. European Medicines Agency (EMA). Benefit-risk methodology 
project work package 3 report: Field tests. London: European 
Medicines Agency. https ://www.ema.europ a.eu/docs/en_GB/
docum ent_libra ry/Repor t/2011/09/WC500 11208 8.pdf. Accessed 
13 Mar 2020.
 13. US Food and Drug Administration. Structured approach to ben-
efit-risk assessment in drug regulatory decision-making. Draft 
PDUFA V implementation plan-February 2013. Fiscal years 
2013–2017.
 14. International Conference of Harmonization (ICH) harmonon-
ised guideline. Revision of M4E guideline on enhancing the 
format and structure of benefit-risk information in ICH Efficacy - 
M4E(R2). 2016. https ://www.ich.org/filea dmin/Publi c_Web_Site/
ICH_Produ cts/CTD/M4E_R2_Effic acy/M4E_R2__Step_4.pdf.
 15. Mt-Isa S, Ouwens M, Robert V, Gebel M, Schacht A, Hirsch I. 
Structured benefit-risk assessment: a review of key publications 
and initiatives on frameworks and methodologies. Pharm Stat. 
2016;15(4):324–32. https ://doi.org/10.1002/pst.1690.
1119Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
 16. Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, 
Downey GF, et al. Recommendations for benefit-risk assessment 
methodologies and visual representations. Pharmacoepidemiol 
Drug Saf. 2016;25(3):251–62. https ://doi.org/10.1002/pds.3958.
 17. Hallgreen CE, van den Ham HA, Mt-Isa S, Ashworth S, Hermann 
R, Hobbiger S, et al. Benefit-risk assessment in a post-market set-
ting: a case study integrating real-life experience into benefit-risk 
methodology. Pharmacoepidemiol Drug Saf. 2014;23(9):974–83. 
https ://doi.org/10.1002/pds.3676.
 18. Hallgreen CE, Mt-Isa S, Lieftucht A, Phillips LD, Hughes D, Tal-
bot S, et al. Literature review of visual representation of the results 
of benefit-risk assessments of medicinal products. Pharmacoepi-
demiol Drug Saf. 2016;25(3):238–50. https ://doi.org/10.1002/
pds.3880.
 19. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW. A review of 
quantitative risk-benefit methodologies for assessing drug safety 
and efficacy-report of the ISPOR risk-benefit management work-
ing group. Value Health. 2010;13(5):657–66. https ://doi.org/10.
1111/j.1524-4733.2010.00725 .x.
 20. European Medicines Agency (EMA). Benefit-risk methodology 
project work package 2 report: Applicability of current tools ans 
processes for regulatory benefit-risk assessment. London: Euro-
pean Medicines Agency. https ://www.ema.europ a.eu/docs/en_GB/
docum ent_libra ry/Repor t/2010/10/WC500 09775 0.pdf. Accessed 
31 Aug 2010.
 21. ADVANCE—Accelerated development of vaccine benefit-
risk collaboration in Europe. https ://www.advan ce-vacci nes.
eu/?page=descr iptio n.
 22. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, 
Petersen I, et al. The REporting of studies Conducted using Obser-
vational Routinely-collected health Data (RECORD) statement. 
PLoS Med. 2015;12(10):e1001885. https ://doi.org/10.1371/journ 
al.pmed.10018 85.
 23. Farrugia MK, Kirsch AJ. Application of the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) 
statement to publications on endoscopic treatment for vesi-
coureteral reflux. J Pediatr Urol. 2017;13(3):320–5. https ://doi.
org/10.1016/j.jpuro l.2017.02.005.
 24. Noah N. The STROBE initiative: STrengthening the Reporting 
of OBservational studies in Epidemiology (STROBE). Epidemiol 
Infect. 2008;136(7):865. https ://doi.org/10.1017/S0950 26880 
80007 33.
 25. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, 
Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE): explanation 
and elaboration. Int J Surg. 2014;12(12):1500–24. https ://doi.
org/10.1016/j.ijsu.2014.07.014.
 26. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Van-
denbroucke JP, et al. The Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) Statement: guidelines 
for reporting observational studies. Int J Surg. 2014;12(12):1495–
9. https ://doi.org/10.1016/j.ijsu.2014.07.013.
 27. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, 
Greenberg D, et al. Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS)—explanation and elaboration: 
a report of the ISPOR Health Economic Evaluation Publication 
Guidelines Good Reporting Practices Task Force. Value Health. 
2013;16(2):231–50. https ://doi.org/10.1016/j.jval.2013.02.002.
 28. Lowe HJ, Barnett GO. Understanding and using the medical sub-
ject headings (MeSH) vocabulary to perform literature searches. 
JAMA. 1994;271(14):1103–8.
 29. Pharmacoepidemiological Research on Outcomes of Therapeutics 
(PROTECT) consortium in Europe. Glossary. https ://www.prote 
ctben efitr isk.eu/gnr.html. Accessed 13 Mar 2020.
 30. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination 
programmes: a focused review of modelling approaches. Phar-
macoeconomics. 2008;26(3):191–21515.
 31. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson 
TR. Quality of nonstructured and structured abstracts of origi-
nal research articles in the British Medical Journal, the Canadian 
Medical Association Journal and the Journal of the American 
Medical Association. CMAJ. 1994;150(10):1611–5.
 32. Cals JW, Kotz D. Effective writing and publishing scientific 
papers, part III: introduction. J Clin Epidemiol. 2013;66(7):702. 
https ://doi.org/10.1016/j.jclin epi.2013.01.004.
 33. Kaat Bollaerts, John Weil. Accelerated Development of VAccine 
beNefit-risk Collaboration in Europe (ADVANCE).WP4–Methods 
for burden of disease, vaccination coverage, vaccine safety and 
effectiveness, impact and benefit-risk 2017. https ://www.advan 
ce-vacci nes.eu/app/archi vos/publi cacio n/44/ADVAN CE_WP4_
D4.9_White _Paper _v1.pdf. Accessed 13 Mar 2020.
 34. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Per-
tussis in adolescents and adults: should we vaccinate? Pediatrics. 
2005;115(6):1675–84. https ://doi.org/10.1542/peds.2004-2509.
 35. Koplan JP, Schoenbaum SC, Weinstein MC, Fraser DW. Pertussis 
vaccine; an analysis of benefits, risks and costs. N Engl J Med. 
1979;301(17):906–11.
 36. Tosti ME, Traversa G, Bianco E, Mele A. Multiple sclerosis and 
vaccination against hepatitis B: analysis of risk benefit profile. Ital 
J Gastroenterol Hepatol. 1999;31(5):388–91.
 37. Jeffery RW. Risk behaviors and health. Contrasting individual and 
population perspectives. Am Psychol. 1989;44(9):1194–202.
 38. Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and 
indirect effects in vaccine efficacy and effectiveness. Am J Epi-
demiol. 1991;133(4):323–31. https ://doi.org/10.1093/oxfor djour 
nals.aje.a1158 84.
 39. Haber M, Longini IM Jr, Halloran ME. Measures of the effects 
of vaccination in a randomly mixing population. Int J Epidemiol. 
1991;20(1):300–10. https ://doi.org/10.1093/ije/20.1.300.
 40. Meltzer MI. Risks and benefits of preexposure and postexposure 
smallpox vaccination. Emerg Infect Dis. 2003;9(11):1363–70. 
https ://doi.org/10.3201/eid09 11.03036 9.
 41. Rothberg M, Bennish ML, Kao JS, Wong JB. Do the benefits of 
varicella vaccination outweigh the long-term risks? A decision-
analytic model for policymakers and pediatricians. Clin Infect Dis. 
2002;34(7):885–94. https ://doi.org/10.1086/33895 6.
 42. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for 
evaluating different efficacy and effectiveness aspects of vaccines. 
Am J Epidemiol. 1997;146(10):789–803.
 43. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects 
and impact of vaccination programmes in post-licensure studies. 
Vaccine. 2013;31(48):5634–42. https ://doi.org/10.1016/j.vacci 
ne.2013.07.006.
 44. Yung CF, Chan SP, Soh S, Tan A, Thoon KC. Intussusception and 
monovalent rotavirus vaccination in Singapore: self-controlled 
case series and risk-benefit study. J Pediatr. 2015;167(1):163–8.
e1. https ://doi.org/10.1016/j.jpeds .2015.03.038.
 45. York Health Economics Consortium (YHEC). A Glossary of 
Health Economic Terms; 2016. https ://www.yhec.co.uk/tools 
-resou rces/gloss ary/. Accessed 13 Mar 2020.
 46. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete 
choice experiments to elicit preferences. Qual Health Care. 
2001;10(Suppl 1):i55–60.
 47. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for 
health care. BMJ. 2000;320(7248):1530–3.
 48. Walker S, Liberti L, McAuslane N, Levitan BS. Refining the 
benefit-risk framework for the assessment of medicines: valuing 
and weighting benefit and risk parameters. Clin Pharmacol Ther. 
2011;89(2):179–82. https ://doi.org/10.1038/clpt.2010.290.
1120 H. Arlegui et al.
 49. Levitan BS, Andrews EB, Gilsenan A, Ferguson J, Noel RA, 
Coplan PM, et  al. Application of the BRAT framework to 
case studies: observations and insights. Clin Pharmacol Ther. 
2011;89(2):217–24. https ://doi.org/10.1038/clpt.2010.280.
 50. Vietri JT, Chapman GB, Li M, Galvani AP. Preferences for HPV 
vaccination in parent-child dyads: similarities and acknowl-
edged differences. Prev Med. 2011;52(5):405–6. https ://doi.
org/10.1016/j.ypmed .2011.03.002.
 51. Buchanan A, Brock DW. Deciding for others. Milbank Q. 
1986;64(Suppl. 2):17–94.
 52. Clark M, Cameron DW. The benefits and risks of bacille Cal-
mette-Guerin vaccination among infants at high risk for both 
tuberculosis and severe combined immunodeficiency: assess-
ment by Markov model. BMC Pediatr. 2006;6:5. https ://doi.
org/10.1186/1471-2431-6-5.
 53. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, 
Edmunds J, et al. Dynamic transmission modeling: a report of the 
ISPOR-SMDM Modeling Good Research Practices Task Force–
5. Value Health. 2012;15(6):828–34. https ://doi.org/10.1016/j.
jval.2012.06.011.
 54. Claxton K, Paulden M, Gravelle H, Brouwer W, Culyer AJ. Dis-
counting and decision making in the economic evaluation of 
health-care technologies. Health Econ. 2011;20(1):2–15. https ://
doi.org/10.1002/hec.1612.
 55. Jit M, Mibei W. Discounting in the evaluation of the cost-
effectiveness of a vaccination programme: a critical review. 
Vaccine. 2015;33(32):3788–94. https ://doi.org/10.1016/j.vacci 
ne.2015.06.084.
 56. Cho BH, Clark TA, Messonnier NE, Ortega-Sanchez IR, Wein-
traub E, Messonnier ML. MCV vaccination in the presence of vac-
cine-associated Guillain–Barre syndrome risk: a decision analysis 
approach. Vaccine. 2010;28(3):817–22. https ://doi.org/10.1016/j.
vacci ne.2009.10.050.
 57. Barton P, Bryan S, Robinson S. Modelling in the economic evalu-
ation of health care: selecting the appropriate approach. J Health 
Serv Res Policy. 2004;9(2):110–8. https ://doi.org/10.1258/13558 
19043 22987 535.
 58. Brinsmead R, Hill S, Walker D. Are economic evaluations of 
vaccines useful to decision-makers? Case study of Haemophilus 
influenzae type b vaccines. Pediatr Infect Dis J. 2004;23(1):32–7. 
https ://doi.org/10.1097/01.inf.00001 05104 .39284 .a3.
 59. Kuntz K, Sainfort F, Butler M, Taylor, B, Kulasingam, S, Gregory 
S, et al. Decision and simulation modeling in systematic reviews. 
Methods Research Report. (Prepared by the University of Min-
nesota Evidence-based Practice Center under Contract No. 290-
2007-10064-I.) AHRQ Publication No. 11(13)-EHC037-EF. 
Rockville, MD: Agency for Healthcare Research and Quality; 
2013. www.effec tiveh ealth care.ahrq.gov/repor ts/final .cfm.
 60. Maro JC, Fryback DG, Lieu TA, Lee GM, Martin DB. Responding 
to vaccine safety signals during pandemic influenza: a modeling 
study. PLoS ONE. 2014;9(12):e115553. https ://doi.org/10.1371/
journ al.pone.01155 53.
 61. Carlin JB, Macartney KK, Lee KJ, Quinn HE, Buttery J, Lopert R, 
et al. Intussusception risk and disease prevention associated with 
rotavirus vaccines in Australia’s National Immunization Program. 
Clin Infect Dis. 2013;57(10):1427–34. https ://doi.org/10.1093/cid/
cit52 0.
 62. Saramago P, Manca A, Sutton AJ. Deriving input param-
eters for cost-effectiveness modeling: taxonomy of data types 
and approaches to their statistical synthesis. Value Health. 
2012;15(5):639–49. https ://doi.org/10.1016/j.jval.2012.02.009.
 63. Chen RT, Orenstein WA. Epidemiologic methods in immunization 
programs. Epidemiol Rev. 1996;18(2):99–117.
 64. Ledent E, Lieftucht A, Buyse H, Sugiyama K, McK-
enna M, Holl K. Post-marketing benefit-risk assessment of 
rotavirus vaccination in Japan: a simulation and modelling analy-
sis. Drug Saf. 2016;39(3):219–30. https ://doi.org/10.1007/s4026 
4-015-0376-7.
 65. Ledent E, Arlegui H, Buyse H, Basile P, Karkada N, Praet N, et al. 
Benefit versus risk assessment of rotavirus vaccination in France: 
a simulation and modeling analysis. BioDrugs. 2018;32(2):139–
52. https ://doi.org/10.1007/s4025 9-018-0273-6.
 66. Brennan A, Akehurst R. Modelling in health economic evalua-
tion. What is its place? What is its value? Pharmacoeconomics. 
2000;17(5):445–59.
 67. Clark A, Tate J, Parashar U, Jit M, Hasso-Agopsowicz M, Hen-
schke N, et al. Mortality reduction benefits and intussusception 
risks of rotavirus vaccination in 135 low-income and middle-
income countries: a modelling analysis of current and alternative 
schedules. Lancet Glob Health. 2019;7(11):E1541–E15521552. 
https ://doi.org/10.1016/s2214 -109x(19)30412 -7.
 68. Phillips LD, Fasolo B, Zafiropoulous N, Eichler HG, Ehmann 
F, Jekerle V, et al. Modelling the risk-benefit impact of H1N1 
influenza vaccines. Eur J Public Health. 2013;23(4):674–8. https 
://doi.org/10.1093/eurpu b/ckt00 6.
 69. Bruun T, Watle SSV, Tveteraas IH, Flem E. Intussusception 
among Norwegian children: what to expect after introduction of 
rotavirus vaccination? Vaccine. 2019;37(38):5717–23. https ://doi.
org/10.1016/j.vacci ne.2019.06.058.
 70. Manissero D, Lopalco PL, Levy-Bruhl D, Ciofi Degli Atti ML, 
Giesecke J. Assessing the impact of different BCG vaccination 
strategies on severe childhood TB in low-intermediate prevalence 
settings. Vaccine. 2008;26(18):2253–9. https ://doi.org/10.1016/j.
vacci ne.2008.02.038.
 71. Ledogar RJ, Fleming J, Andersson N. Knowledge synthesis of 
benefits and adverse effects of measles vaccination: the Lasbela 
balance sheet. BMC Int Health Hum Rights. 2009;9(Suppl 1):S6. 
https ://doi.org/10.1186/1472-698x-9-s1-s6.
 72. Dunn AG, Coiera E, Mandl KD, Bourgeois FT. Conflict of interest 
disclosure in biomedical research: a review of current practices, 
biases, and the role of public registries in improving transpar-
ency. Res Integr Peer Rev. 2016. https ://doi.org/10.1186/s4107 
3-016-0006-7.
 73. Rosenberg J, Bauchner H, Backus J, De Leeuw P, Drazen J, Fri-
zelle F, et al. The new ICMJE recommendations. Indian J Med 
Microbiol. 2014;32(3):219–20. https ://doi.org/10.4103/0255-
0857.13654 5.
 74. Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines 
for reporting health research: the EQUATOR network’s survey 
of guideline authors. PLoS Med. 2008;5(6):e139. https ://doi.
org/10.1371/journ al.pmed.00501 39.
 75. Bollaerts K, De Smedt T, Donegan K, Titievsky L, Bauchau V. 
Benefit-risk monitoring of vaccines using an interactive dash-
board: a methodological proposal from the ADVANCE project. 
Drug Saf. 2018;41(8):775–86. https ://doi.org/10.1007/s4026 
4-018-0658-y.
 76. Torcel-Pagnon L, Bauchau V, Mahy P, Tin Tin Htar M, van der 
Sande M, Mahe C, et al. Guidance for the governance of pub-
lic–private collaborations in vaccine post-marketing settings in 
Europe. Vaccine. 2019;37(25):3278–89. https ://doi.org/10.1016/j.
vacci ne.2019.04.073.
 77. Garrison LP Jr, Towse A, Bresnahan BW. Assessing a struc-
tured, quantitative health outcomes approach to drug risk-benefit 
analysis. Health Aff (Millwood). 2007;26(3):684–95. https ://doi.
org/10.1377/hltha ff.26.3.684.
 78. Simera I, Moher D, Hirst A, Hoey J, Schulz KF, Altman DG. 
Transparent and accurate reporting increases reliability, util-
ity, and impact of your research: reporting guidelines and 
the EQUATOR Network. BMC Med. 2010;8:24. https ://doi.
org/10.1186/1741-7015-8-24.
